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Non-intercalating DNA minor-groove binders may effectively inhibit the supercoiling activity of gyrases by influencing the enzyme recognition 
and cleavage site on DNA. For gyrase from Streptomyces noursei a wide range of inhibitory potency for different classes of ligands is observed. 
This can be explained by a number of structural and binding factors of the ligands competing with the gyrase on the target site of DNA, the 
mechanism of which is different from the classical gyrase inhibitors. 
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1. INTRODUCTION 
DNA gyrase is an essential enzyme in the DNA me- 
tabolism of prokaryotes, the function of which includes 
DNA replication, recombination, transcription, chro- 
mosome segregation and the maintenance of the nu- 
cleoid structure in bacteria [l-5]. The enzyme is also 
believed to be the target for certain bacterial growth 
inhibitors, such as coumarins and quinolones [3,4,6,7], 
though the interference of the latter type of inhibitors 
has been attributed to the binding with DNA in the 
enzyme complex [8,9]. The activity of gyrase in vitro is 
related to its ability to induce DNA supercoiling, cate- 
nation or decatenation [2]. 
It has been established that a number of drugs and 
organic agents affecting enzymes of DNA metabolism 
bind in the minor groove of B-DNA by non-intercala- 
tive means (for review see [lo]), and most of these li- 
gands, such as Nt and Dst-3, prefer AT-rich sequences 
[ 10,111. A new synthetic type of drug, lexitropsins, show 
a reduced affinity for AT pairs, but may also accept GC 
pairs [13-151. Synthetic minor groove binders were de- 
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Abbrevrationst Dst-3, distamycin A; Nt=Nt-PyPy, netropsin contain- 
ing methylpyrrole (Py); Nt-PyIm, Nt-ImPy, Nt-Im,, netropsin analogs 
(lexitropsins) containing methylimidazole (Im) and (or) methylpyrrole 
(Py); bis-Nt-X (X=5,6,8), dimeric netropsin analogs linked by X meth- 
yleneresidues(X=5,6,8); DAPI,4’,6-di-amidino-phenylindole; Hoechst 
33258, 2-(4-hydroxyphenyl)-5-[5-(4-methyl-piperazin-1 -yl)-benzimi- 
dazole-2-yllbenzimidazole; SN-6999, NSC-101327, SN-6132, SN- 
6131, SN-16814, SN-1871: bisquatemary ammonium heterocycles 
(structures are given in [10,22]); SDS, sodium dodecylsulfate. 
signed to develop modified agents reading defined se- 
quences [16]. This includes a series of netropsin dimers 
containing two netropsin units [17]. The interference of 
some minor-groove binders with the activity of mam- 
malian topoisomerase II has been reported [ 18-201. Re- 
cently, we showed that Dst-3 is an inhibitor of gyrase 
activity [21]. 
In this report we demonstrate that netropsin and a 
variety of minor groove binders with different chemical 
structures are potent gyrase inhibitors, the effectiveness 
of which depends significantly on the nature and bind- 
ing ability of the ligand to DNA. The molecular mech- 
anism of interference clearly differs from that of classi- 
cal gyrase inhibitors. 
2. MATERIALS AND METHODS 
2.1. Minor groove binding ligands 
Dst-3 was obtained from Sigma (St. Louis, MO); Nt was a highly 
purified product isolated from Streptomyces netropsis [lo]. The lex- 
itropsins Nt-ImPy, Nt-Im, and bis-Nt-X (X = 5,6,8) have been re- 
ported previously [14,23]. DAPI, Chromomycin A, and Hoechst 
33258 were purchased from Fluka and Serva (Heidelberg). Bisquater- 
nary ammonium heterocyclic compounds were gifts from Dr. B. 
Baguley (Auckland, New Zealand). DNA binding data of various 
ligands investigated are described in the reference given in Table I. 
Structures of ligands are summarized elsewhere [10,22]. 
2.2. Enzymes and assay 
Purification of gyrase from Streptomyces noursei s reported in a 
forthcoming paper (J. Stiirl et al.). 
Assay of gyrase-mediated supercoiling of relaxed pBR322 DNA: 
the reaction mixture (20 ~1) contained 40 mM Tris-HCI (pH 7.5), 19 
mM KH2P0,, 34 mM KCI, 5 mM spermidine, 3.6 mg/ml bovine serum 
albumin. 100 @ml t-RNA, 1.6 mM MgCI,, 1.4 mM ATP, 0.5 pg 
relaxed DNA plus one unit of gyrase. One unit is defined as the 
amount of enzyme required to convert 0.5 pg relaxed plasmid DNA 
into its supercoiled form in 45 min at 30°C. The enzyme reaction was 
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terminated with 3 ~1 stopper solution containing 10% SDS, 0.05% 
bromophenol blue and 50% glycerol. Samples were electrophoresed 
on 1% agarose, stained with ethidium bromide (0.5 ,&ml) and photo- 
graphed. The negatives were scanned on a computerized Bio-Rad 
densitometer. The inhibitory effect of the ligands on gyrase activity 
was detected from the amounts of closed circular DNA, which were 
most pronounced. 
3. RESULTS AND DISCUSSION 
The interference of various non-intercalating minor 
groove binders with the catalytic activity of DNA gy- 
rases from S. noursei and E. coli was examined by the 
enzyme-mediated supercoiling reaction. As an example 
the gel electrophoretic analysis of the influence of in- 
creasing amounts of the AT-specific DNA binding drug 
Nt on the supercoiling activity of S. noursei gyrase is 
shown in Fig. 1. The enzyme without Nt produces su- 
percoiled DNA (lane 1). Addition of 1 and 2.5 ,uM Nt 
(lanes 2,3) has no significant effect whereas concentra- 
tions of 5, 10 and 20 ,uM Nt (lanes 4-6) progressively 
inhibit the formation of supercoiled DNA. At 30 PM 
Nt, the enzyme reaction is nearly completely blocked 
(lane 7). 
It was of interest to investigate whether other minor 
groove binders having different chemical structures 
show a correlation with their functional effects on gy- 
rase supercoiling activity. The influence of increasing 
ligand concentrations on gyrase activity for six repre- 
sentative minor groove binders is shown in Fig. 2. Dst-3 
most strongly inhibits the enzyme activity followed by 
Nt, chromomycin A3, SN-6999 and bis-Nt-6. SN- 18071 
is ineffective in the concentration range up to 30 ,uM at 
which Dst-3, Nt and chromomycin A, completely block 
the gyrase activity (Fig. 2, curves l-3). SN-6999 or bis- 
Nt-6 show half of the inhibitory effect (curves 4,5). In 
the case of SN-18071 IC,, is 150 ,uM (curve 6). This 
means that SN-18071 is nearly inactive relative to the 
other minor groove binders (Fig. 2). 
The antigyrase activities of the four groups of DNA 
binding ligands investigated for the S. noursei enzyme 
are summarized in Table I. These effects of minor 
groove binders are similar for the E. cofi gyrase (data 
not shown). As indicated by the IC,, and IQ,, values, 
Dst-3, Nt and the imidazole-containing lexitropsins as 
well as DAPI and chromomycin A, show most pro- 
nounced inhibitory effects whereas Hoechst 33258 and 
ligands of group 3 and 4 are moderate or weak inhib- 
itors of gyrase activity. All these compounds bind to 
DNA in the minor groove (for review see [lo]). In view 
of the properties of these ligands one might expect that 
the antigyrase activity is related to their DNA-binding 
parameters. However, no direct correlation of the effi- 
ciency of ligand-induced modulation of the enzyme ac- 
tivity to their DNA-binding properties could be found. 
This is exemplified by the following considerations: the 
AT-specific minor groove binder, Nt, with an overall 
association constant of K, = 2 x 106*M-’ for calf thymus 
DNA [lo] and K, - 1 08.M-’ for poly( dA-dT)*poly(dA- 
dT) [lo] shows similar I&, and IC,, values as chro- 
momycin A,, which is highly GC-specific [25] with a K, 
Fig. 1. Effect of netropsin f 
12345678 
:Nt) on the supercoiling activity of gyrase from S. nourse~. Lanes: 1, supercoiled pBR322 DNA; 8, I 
226: 1, 2.5, 5, IO, 20, 30 ,uM Nt, respectively. 
.elaxed 1 DNA; lanes 
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Fig. 2. Inhibitory effect of some minor groove binders on supercoiling activity of gyrase. Attached numbers indicate drugs: 1, Dst-3; 2, Nt; 3, 
chromomycin A,; 4, SN 6999; 5, bis-Ntd; 6, SN-18071. 
value for the calf thymus DNA-Me*+ complex of 
-lO”*M-’ 1261. Dst-3 appears to be the most efficient 
gyrase inhibitor (Table I); like Nt it prefers AT base 
pairs, but it may accept one GC pair 128,293. Dst-3 
shows an overall K, value of 1.2 x 106.M-’ for calf 
thymus DNA and a K, of 1.8 x lO’*M-’ for poly(dA- 
dT).poly(dA-dT) [ 10,281, which is one characteristic pa- 
rameter for its AT-affinity. For Nt-Im, a strongly re- 
duced AT-affinity and a high acceptance of GC pairs 
was demonstrated with a binding constant of K, = 1.06 
x 106*M-’ for calf thymus DNA [ 131. As indicated by 
the IC,, and I&, values for Nt-Im, the inhibitory effect 
is comparable with that of Dst-3 or Nt (Table I). These 
features demonstrate that base pair preference and 
binding strength alone cannot be regarded as factors 
responsible for the antigyrase activity of the ligands. On 
the other hand, it was reported that bidentate binding 
to DNA of bi-functional netropsin analogs can increase 
the inhibitory effect of mammalian topoisomerase II 
[19]. In contrast to this finding we observe the reverse 
effect for the inhibition of gyrase activity: bis-netropsins 
show a significantly weaker antigyrase activity com- 
Table I 
Inhibition of DNA supercoiling activity of gyrase from S. noursei by non-intercalating DNA-binding ligands 
Group Ligand Base pair affinity 
AT GC 
DNA binding 
references 
1 Dst-3 8 2.7 
Nt-Im, 16 8.4 
Nt-PyIm 20 15 
Nt-ImPy 18 12 
Nt-PyPy 25 8 
DAPI 17 
Chromomycin AZ 23 
Hoechst 33258 68 
Bis-Nt5 
Bis-Nt-6 
Bis-Nt-8 
SN-6999 62 23 
NSC-101327 79 38 
SN-6132 91 46 
SN-6131 100 50 
SN-18071 350 150 
SN-16814 no inhibition - 
58 25 ++ 
111 34 ++ 
113 39 ++ 
8.8 
12 
33 
G + + ++ 
+ 
++ 
++ 
+ 
++ 
+ 
+ 
+ 
(+I 
(+I 
(+I 
HO,121 
113,151 
[13,151 
[13,151 
IlO. 
[lo,271 
125.261 
[IO,401 
s 71 
[171 
[I71 
[lo,221 
[lo,221 
[22,241 
t22.241 
t10,221 
PO,221 
IC, and IC,, con~ntration of the ligand at 50% and 90% inhibition, respectively, of the enz~e-mediate supercoiling. 
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pared with Nt as indicated by much higher IC,, and IC,, 
values (Table I, group 3). Thus, it appears that elonga- 
tion of the ligand by increasing number of N-methyl- 
pyrrole units contained in the bis-netropsin analogs 
does not enhance, but instead lowers, the inhibitory 
effect on gyrase activity. These different effects of 
minor-groove binders observed for gyrase (Fig. 2, Table 
I) and eukaryotic topoisomerase II ([19] and unpub- 
lished data of the authors) may reside in the differences 
in the molecular interaction mechanisms between the 
two types of enzymes with DNA. While the production 
of double-strand breaks is a common reaction of both 
enzymes, the complexes formed with double-stranded 
DNA involve distinctly different elements in the interac- 
tion. Eukaryotic topoisomerase II exists as a homo- 
dimer containing sequence regions homologous to the 
gyr A and gyr B subunits of gyrase [30] and it binds 
preferentially to negatively supercoiled DNA [30]. Gy- 
rase is a tetramer consisting of gyr A and gyr B subunits 
as dimers [31], which interact with the DNA target site 
by wrapping the DNA on the outside of the enzyme 
forming a gyrase-DNA complex [32]. This distinguishes 
DNA-bound gyrase from that of eukaryotic topoisom- 
erase II. DNA in this complex could be more readily 
accessible to smaller minor-groove binders, such as Nt, 
than to much longer ones, such as bis-netropsins (Table 
I). Consequently, it seems that coiling of DNA in the 
complex with gyrase together with the affinity to the 
DNA target sequence, could influence the competitive 
interaction with the ligand. 
To test that minor-groove binders may directly block 
the enzyme from binding to its cleavage site, SDS treat- 
ment of the gyrase reaction was applied before electro- 
phoresis. SDS rapidly denatures the complex in which 
DNA has been cleaved by gyrase and in the presence of 
the inhibitor oxolinic acid cleaved DNA can be detected 
[33]. By using ciprofloxacin as a reference for the ap- 
pearance of linear DNA (Fig. 3, lanes 3 and 6) which 
indicates formation of a cleavable complex, it follows 
from the absence of linear DNA in the presence of high 
inhibitory concentrations of Nt and Dst-3 (Fig. 3, lanes 
1,2.4 and 5) that minor-groove binders prevent forma- 
tion of a cleavable complex. This feature is illustrated 
in Fig. 4 by a schematic drawing based on the model of 
Shen et al. [34]. The formation of this complex mediated 
by interaction with DNA of gyrase via tyrosine as active 
site of subunit gyr A is totally blocked by minor-groove 
binding of Nt. It is plausible that the minor groove plays 
a role for the access of the enzyme through gyr A on 
DNA. Most probably, minor-groove binding of Nt and 
related agents cause a displacement of gyrase from its 
DNA target region rather than a dislocation (Fig. 4~). 
Preliminary gel retardation experiments with DNA 
fragments (Simon, H., unpublished data) support this 
suggestion. To explain the differences of the inhibitory 
potency of various minor-groove binders on gyrase ac- 
tivity (Table I), a number of additional factors deter- 
mining the interaction mechanism have to be consid- 
ered, such as binding strength, site size, AT- vs. GC- 
affinity and conformational effects, as well as the geom- 
etry and flexibility of the ligands. An essential aspect 
resides in the affinity of the ligands to the enzyme recog- 
123456789 
Fig. 3. Comparative inhibitory effects of Nt, Dst-3 and ciprofloxacin on supercoiling activity of gyrase from E. coli in the absence of ATP, after 
SDS treatment. AT 200 PM drug: lanes 1,4: Dst-3; 2.5: Nt; 3.6: ciprofloxacin; 7: in presence of ATP without drug; 8: pBR322 DNA linearrzed 
wtth EcoRI; 9. wtthout ATP, without drug; R, relaxed: L. hnear; S, supercoiled DNA. 
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Fig. 4. Schematic model of proposed effects for quinolone and minor 
groove binders in the inhibition of gyrase on DNA; a, quinolone- 
DNA binding according to Shen et al. [34]; b, gyrase dislocated and 
c, displaced by netropsin-minor-groove binding. 
nition and cleavage site on DNA. For pBR322 plasmid 
DNA, several strong gyrase sites have been detected by 
using oxolinic acid-mediated DNA cleavage in vitro 
[35,36] and in vivo [33]. Enzyme binding occurs to a 
DNA stretch of at least 120 bp (or larger) whereas a 
region of about 40 bp surrounding the cleavage site is 
most strongly bound [35]. By inspection of the se- 
quences analysed for various strong gyrase cleavage 
sites and surrounding segments in pBR322 DNA [35- 
373 it appears that AT and GC pairs are nearly equally 
distributed in these regions and AT clusters are very 
rare adjacent to the cleavage site. As an example, the 
sequence of a representative strong gyrase site, loca- 
ted at position 990 on the pBR322 map [33,35], is 
as follows: 5’-GA~~AT~~CCCCA~A. 
Most of the four base pair staggered cleavage sites of 
the gyrase contain a higher number of GC pairs, and for 
in vivo assayed sites it was reported that the position 3’ 
to a cut requires G [33]. As mentioned above, AT-se- 
quence specificity of the ligand alone cannot account for 
the competition at the gyrase binding site. Dst-3 binds 
tightly to AT clusters (see binding data discussed 
above), but also accepts a GC pair [28,29] and is known 
to induce confo~ational changes in DNA, such as al- 
losteric or bending effects 137,383. This may explain its 
high inhibitory potency indicated by I& and IC, val- 
ues (Table I, Fig. 2). For the antigyrase activity of Nt, 
which is AT-specific, other factors must be taken into 
account, such as structural effects; e.g. an important 
element in minor groove binding for Nt and the related 
ligands of group 1 (Table I) concerns the high flexibility 
of the oligopeptide structure allowing a proper isoheli- 
cal alignment in the groove [lo]. Nt also induces a local 
stiffening of bound regions [39] achieved by hydrogen 
bonding, electrostatic attraction and van der Waais 
contacts (for review see [lo]). The dicationic nature of 
Nt seems to be an essential factor since the related mono- 
cationic ligand, Dst-2, showed only a poor inhibitory 
effect on gyrase activity [21]. Interestingly Nt-Im,, 
structurally related to Nt, represents apotent antigyrase 
agent, which is even slightly more active than Nt (Table 
I). This dicationic lexitropsin permits GC binding be- 
sides a reduced AT affinity, which therefore can com- 
pete with CC pairs at the gyrase recognition site by 
formation of hydrogen bonds to G-NH2 in the minor 
groove [13,1.5]. In case of DAPI, which shows an AT 
preferred binding to DNA [27], its simultaneous interca- 
lative binding ability to a GC pair [27] may be a possible 
factor contributing to the antigyrase activity, Chro- 
momycin A3 may also effectively compete with gyrase 
at the binding and cleavage site due to its high GC- 
specificity [26] by blocking the G site required at the 
enzyme cutting site. On the other hand bis-netropsins 
(Table I, group 3) are very poor inhibitors which may 
be a consequence of the absence of longer AT-stretches 
required for bidentate binding to compete with the en- 
zyme at the recognition site. For bisquaternary ammo- 
nium heterocyclic ligands (Table I, group 4) their rigid- 
ity may be a factor to explain the lower antigyrase activ- 
ity. 
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